Dr. Higano on Docetaxel for Hormone-Sensitive Prostate Cancer

Celestia Higano, MD
Published Online: Friday, Apr 14, 2017



Celestia Higano, MD, professor of Medicine and Urology, University of Washington, member of the Clinical Research Division at Fred Hutchinson Cancer Research Center, discusses results of docetaxel (Taxotere) versus hormone therapy in patients with metastatic hormone-sensitive prostate cancer.

For the first time, docetaxel demonstrated a very large difference in median overall survival (OS) compared with hormone therapy alone. This is one of the biggest improvements in survival that has been seen in oncology, explains Higano.

One thing to be cautious of is the impact this might have down the line. Docetaxel is usually used for metastatic castration-resistant disease, and now that it is being used for those who have metastatic hormone-sensitive disease, it might not work as well. There are some data that suggest that this happens in the castration-resistant setting, so practitioners will be cognizant of how they place docetaxel in a disease, states Higano.



Celestia Higano, MD, professor of Medicine and Urology, University of Washington, member of the Clinical Research Division at Fred Hutchinson Cancer Research Center, discusses results of docetaxel (Taxotere) versus hormone therapy in patients with metastatic hormone-sensitive prostate cancer.

For the first time, docetaxel demonstrated a very large difference in median overall survival (OS) compared with hormone therapy alone. This is one of the biggest improvements in survival that has been seen in oncology, explains Higano.

One thing to be cautious of is the impact this might have down the line. Docetaxel is usually used for metastatic castration-resistant disease, and now that it is being used for those who have metastatic hormone-sensitive disease, it might not work as well. There are some data that suggest that this happens in the castration-resistant setting, so practitioners will be cognizant of how they place docetaxel in a disease, states Higano.


View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Clinical Vignette Series: 34th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow®Feb 28, 20182.0
Community Practice Connections™: Personalized Sequencing in Castration-Resistant Prostate Cancer: Bridging the Latest Evidence to the Bedside in Clinical ManagementAug 25, 20181.5
Publication Bottom Border
Border Publication
$emailPop$
x